CONMED reported 1Q26 orthopedic sales of $147.7 million, up 6.8% compared to the first quarter of 2025. This marks the third consecutive quarter of mid-single-digit growth for the company, underscoring the success of its BioBrace platform and improving supply chain.
BioBrace is a key driver for CONMED’s long range growth and a core pillar of its sports medicine strategy. As more surgeons adopt the implant, the company is seeing broader utilization across primary repairs and more complex cases.
In addition to the 30 published studies on BioBrace, the company is enrolling a 268-patient randomized controlled trial with expected publication in 2027.
CONMED expects total sales growth between 5% and 6.5% in 2026, implying orthopedic sales in the range of $608 million.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
1Q26
1Q25
$ Chg
% Chg
Trauma
$14.2
$13.3
$1.0
7.5%
Sports Medicine
$133.4
$125.0
$8.4
6.7%
Total
$147.7
$138.3
$9.4
6.8%
Orthopedic Sales by Geography
Region
1Q26
1Q25
$ Chg
% Chg
US
$55.9
$52.5
$3.4
6.5%
OUS
$91.7
$85.7
$6.0
7%
EMEA
$38.5
$35.9
$2.5
7.1%
APAC
$30.8
$27.0
$3.9
14.4%
ROW
$22.4
$22.8
($0.4)
(1.8%)
Total
$147.7
$138.3
$9.4
6.8%
Company Earnings
Amt
% of Sales
Sales
$317.1
Cost of Sales
$133.6
42.1%
Selling and Admin
$141.7
44.7%
R&D
$16.3
5.1%
Other
$11.7
3.7%
Net Earnings
$13.8
4.4%
CONMED reported 1Q26 orthopedic sales of $147.7 million, up 6.8% compared to the first quarter of 2025. This marks the third consecutive quarter of mid-single-digit growth for the company, underscoring the success of its BioBrace platform and improving supply chain.
BioBrace is a key driver for CONMED's long range growth and a core pillar...
CONMED reported 1Q26 orthopedic sales of $147.7 million, up 6.8% compared to the first quarter of 2025. This marks the third consecutive quarter of mid-single-digit growth for the company, underscoring the success of its BioBrace platform and improving supply chain.
BioBrace is a key driver for CONMED’s long range growth and a core pillar of its sports medicine strategy. As more surgeons adopt the implant, the company is seeing broader utilization across primary repairs and more complex cases.
In addition to the 30 published studies on BioBrace, the company is enrolling a 268-patient randomized controlled trial with expected publication in 2027.
CONMED expects total sales growth between 5% and 6.5% in 2026, implying orthopedic sales in the range of $608 million.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
1Q26
1Q25
$ Chg
% Chg
Trauma
$14.2
$13.3
$1.0
7.5%
Sports Medicine
$133.4
$125.0
$8.4
6.7%
Total
$147.7
$138.3
$9.4
6.8%
Orthopedic Sales by Geography
Region
1Q26
1Q25
$ Chg
% Chg
US
$55.9
$52.5
$3.4
6.5%
OUS
$91.7
$85.7
$6.0
7%
EMEA
$38.5
$35.9
$2.5
7.1%
APAC
$30.8
$27.0
$3.9
14.4%
ROW
$22.4
$22.8
($0.4)
(1.8%)
Total
$147.7
$138.3
$9.4
6.8%
Company Earnings
Amt
% of Sales
Sales
$317.1
Cost of Sales
$133.6
42.1%
Selling and Admin
$141.7
44.7%
R&D
$16.3
5.1%
Other
$11.7
3.7%
Net Earnings
$13.8
4.4%
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
